Blood pressure, inflammation, and quality of life in patients treated with different renal replacement therapies.
blood pressure
inflammation
quality of life
renal failure
Journal
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
ISSN: 1744-9987
Titre abrégé: Ther Apher Dial
Pays: Australia
ID NLM: 101181252
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
revised:
18
05
2021
received:
12
03
2021
accepted:
21
05
2021
pubmed:
26
5
2021
medline:
11
2
2022
entrez:
25
5
2021
Statut:
ppublish
Résumé
Our aim was to determine the relationship between the modality of renal replacement therapy and inflammation markers, BP control, and quality of life (QoL). Sixteen hemodialysis, 17 peritoneal dialysis patients, and 27 kidney transplant receivers (KTr) have been included in this study. Short Form-36 (SF-36) for the evaluation of QoL and ambulatory BP monitoring were performed on the same day. Erythrocyte sedimentation rate, CRP, IL-6, and IL-10 were measured. While the mean IL-10, IL-6, and CRP levels were the highest in the dialysis groups, there were no significantly differences any parameters for all groups. QoL was better in the KTr almost as in healthy controls but worse in the dialysis patients. It should be taken into account that hypertension may occur at night even if the daytime BP is normal in KTr.
Identifiants
pubmed: 34032378
doi: 10.1111/1744-9987.13692
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
115-121Subventions
Organisme : Çukurova University Scientific Research
ID : TFLTP201231
Informations de copyright
© 2021 International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy.
Références
Perloff D, Sokolow M, Cowan RM, Juster RP. Prognostic value of ambulatory blood pressure measurements: further analyses. J Hypertens. 1989;7(3):S3-S10.
Baumgart P, Walger P, Gemen S, von Eiff M, Raidt H, Rahn KH. Blood pressure elevation during the night in chronic renal failure, hemodialysis and after renal transplantation. Nephron. 1991;57:293-8.
Portaluppi F, Montanari L, Massari M, Di Chiara V, Capanna M. Loss of nocturnal decline of blood pressure in hypertension due to chronic renal failure. Am J Hypertens. 1991;4:20-6.
Cugini P, Palestini M, Di Palma L, Riggio MU, Cavallini M, Leone G. Overall biostatistical approach to the 24-h behavior of arterial blood pressure in chronic uremic normotensive patients [in Italian]. Recenti Prog Med. 1990;81:252-8.
Kaysen GA, Dubin JA, Muller HG, Mitch WE, Levin NW. Levels of alpha1 acid glycoprotein and ceruloplasmin predict future albumin levels in hemodialysis patients. Kidney Int. 2001;60:2360-6.
Ulrich C, Keil K, Hermann W, Kuhlmann M, et al. Procalcitonin: a further acute phase parameter in patients undergoing haemodialysis. J Am Soc Nephrol. 2000;11:501A.
Okpechi IG, Nthite T, Swanepoel CR. Health-related quality of life in patients on hemodialysis and peritoneal dialysis. Saudi J Kidney Dis Transpl. 2013;24:519-26. https://doi.org/10.4103/1319-2442.111036.
Goncalves FA, Dalosso IF, Borba JMC, Bucaneve J, Valerio NMP, Okamoto CT, et al. Quality of life in chronic renal patients on hemodialysis or peritoneal dialysis: a comparative study in a referral service of Curitiba - PR. J Bras Nefrol. 2015;37:467-74. https://doi.org/10.5935/0101-2800.20150074.
Frimat L, Durand PY, Loos-Ayav C, Villar E, Panescu V, Briançon S, et al. Impact of first dialysis modality on outcome of patients contraindicated for kidney transplant. Perit Dial Int. 2006;26:231-9.
Al Wakeel J, Al Harbi A, Bayoumi M, Al-Suwaida K, Al Ghonaim M, Mishkiry A. Quality of life in hemodialysis and peritoneal dialysis patients in Saudi Arabia. Ann Saudi Med. 2012;32:570-4. https://doi.org/10.5144/0256-4947.2012.570.
Kim JY, Kim B, Park KS, Choi JY, Seo JJ, Park SH, et al. Health-related quality of life with KDQOL-36 and its association with self-efficacy and treatment satisfaction in Korean dialysis patients. Qual Life Res. 2013;22:753-8. https://doi.org/10.1007/s11136-012-0203-x.
Merkus MP, Jager KJ, Dekker FW, de Haan RJ, Boeschoten EW, Krediet RT, et al. Quality of life over time in dialysis: The Netherlands Cooperative Study on the Adequacy of Dialysis. Kidney Int. 1999;56:720-8. https://doi.org/10.1046/j.1523-1755.1999.00563.x.
Okpechi IG, Nthite T, Swanepoel CR. Health-related quality of life in patients on hemodialysis and peritoneal dialysis. Saudi J Kidney Dis Transpl. 2013;24:519-26. https://doi.org/10.4103/1319-2442.111036.
Kang SH, Do JY, Lee SY, Kim JC. Effect of dialysis modality on frailty phenotype, disability, and health-related quality of life in maintenance dialysis patients. PLoS One. 2017;12:e0176814. https://doi.org/10.1371/journal.pone.0176814.
Wu AW, Fink NE, Marsh-Manzi JV, Meyer KB, Finkelstein FO, Chapman MM, et al. Changes in quality of life during hemodialysis and peritoneal dialysis treatment: generic and disease specific measures. J Am Soc Nephrol. 2004;15:743-53. https://doi.org/10.1097/01.ASN.0000113315.81448.CA.
Dąbrowska-Bender M, Dykowska G, Żuk W, Milewska M, Staniszewska A. The impact on quality of life of dialysis patients with renal insufficiency. Patient Prefer Adherence. 2018;12:577-83.
Korkut Y. Ferrans ve Powers'ın Diyaliz Hastaları İçin Yaşam Kalitesi Endeksinin Güvenirlik ve Geçerlik Çalışması. Nöropsikiyatri Arşivi. 2007;44:14-8.
Simmons RG, Anderson CR, Abress LK. Quality of life and rehabilitation differences among four end-stage renal disease therapy groups. Scand J Urol Nephrol Suppl. 1990;131:7-22.
Chkhotua A, Pantsulaia T, Managadze L. The quality of life analysis in renal transplant recipients and dialysis patients. Georgian Med News. 2011 Nov;11:10-7.
Avramovic M, Stefanovic V. Health-related quality of life in different stages of renal failure. Artif Organs. 2012;36:581-9. https://doi.org/10.1111/j.1525-1594.2011.01429.x.
Gawin J, Rifai N, Buring JE, Ridker PM. Blood pressure, CRP and Risk of future Cardiovascüler events. Circulation. 2003;122:1985-96.
Fujisawa M, Ichikawa Y, Yoshiya K. Assessment of health-related quality of life in renal transplant and hemodialysis patients using the SF-36 health survey. Urology. 2000;56:201-6.
Verdecchia P, Schillaci G, Guerrieri M, Gatteschi C, Benemio G, Boldrini F, et al. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation. 1990;81:528-36.
White WB, Schulman P, McCabe EJ, Dey HM. Average daily blood pressure, not office blood pressure, determines cardiac function in patients with hypertension. JAMA. 1989;261:873-7.
White WB, Dey HM, Schulman P. Assessment of the daily blood pressure load as a determinant of cardiac function in patients with mild-to-moderate hypertension. Am Heart J. 1989;118:782-95.
Li J, Wang F, Jian G, Ma N. Analysis of 24-hour ambulatory blood pressure monitoring in patients with diabetic nephropathy: a hospital-based study. Clin Nephrol. 2013 Mar;79:199-205.
Ibernon M, Moreso F, Sarrias X, Sarrias M, Grinyó JM, Fernandez-Real JM, et al. Reverse dipper pattern of blood pressure at 3 months is associated with inflammation and outcome after renal transplantation. Nephrol Dial Transplant. 2012 May;27:2089-95.
Toprak A, Koc M, Tezcan H, Ozener IC, Oktay A, Akoglu E. Night-time blood pressure load is associated with higher left ventricular mass index in renal transplant recipients. J Hum Hypertens. 2003;17:239-44.
Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999;55:648-58.
Rao M, Guo D, Perianayagam MC, Tighiouart H, Jaber BL, Pereira BJ, et al. Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2005;45:324-33.
De Miguel C, Rudemiller NP, Abais JM, Mattson DL. Inflammation and hypertension: new understandings and potential therapeutic targets. Curr Hypertens Rep. 2015;17:507.
Barreto DV, Barreto FC, Liabeuf S, Temmar M, Lemke HD, Tribouilloy C, et al. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int. 2010;77:550-6. https://doi.org/10.1038/ki.2009.503.